Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.46 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.46 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678922 | 0.97 | MCHR1 (0.53) | MCHR1DNMT1DNMT3ADNMT3LATR | |
| SCHEMBL682918 | 0.95 | MCHR1 (0.49) | MCHR1DNMT1DNMT3ADNMT3LATR | |
| SCHEMBL12529830 | 0.76 | MCHR1 (0.89) | MCHR1 | |
| SCHEMBL682916 | 0.74 | DNMT1 (0.60) | DNMT1DNMT3ADNMT3L | |
| SCHEMBL12529621 | 0.74 | MCHR1 (0.89) | MCHR1 | |
| SCHEMBL12547879 | 0.73 | MCHR1 (0.87) | MCHR1 | |
| SCHEMBL686753 | 0.72 | DNMT1 (0.50) | DNMT1DNMT3ADNMT3L | |
| SCHEMBL683733 | 0.72 | DNMT1 (0.50) | MCHR1DNMT1DNMT3ADNMT3L | |
| SCHEMBL12531078 | 0.72 | MCHR1 (0.74) | MCHR1 | |
| SCHEMBL683853 | 0.71 | DNMT1 (0.49) | MCHR1DNMT1DNMT3ADNMT3L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | MCHR1 4277/4885DNMT1 1209/4885DNMT3A 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.